TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30256751
Drug: HMB/Arg/Gln (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/Arg/Gln (1.2 g HMB, 7 g L‐Arg, and 7 g L‐Gln)
Study: 20959720
Drug: UAG 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAG 200 μg
Study: 20959720
Drug: UAG 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAG 100 μg + AG 100 μg (Comb)
Study: 11291357
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg four times a day)
Study: 9211127
Drug: naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (0.8 mg i.v. bolus, followed by infusion of 1.6 mg/h for 120')
Study: 9211127
Drug: alpha-MSH (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-MSH (2.5 mg i.v. bolus)
Study: 9211127
Drug: naloxone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone + alpha-MSH (2.5 mg i.v. 15' after commencement of the naloxone infusion)
Study: 9211127
Drug: GnRH +
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH + naloxone (100 micrograms i.v. 15' after commencement of the naloxone infusion)
Study: 9211127
Drug: GnRH +
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH + alpha-MSH (100 micrograms i.v. 15' after commencement of the naloxone infusion)
Study: 9211127
Drug: placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (150 nmol/l NaCl solution)
Study: 7699834
Drug: SY5555 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 at a dose of 5 mg/kg
Study: 7699834
Drug: SY5555 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 at a dose of 10 mg/kg
Study: 7699834
Drug: SY5555 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 at a dose of 10 mg/kg (infants)
Study: 7699834
Drug: SY5555 (comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 (comparison with other antibiotics)
Study: 2705661
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with birch pollen allergen preparations, n = 42
Study: 2705661
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with birch pollen allergen preparations, n = 14
Study: 2705661
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral immunotherapy, n = 16
Study: 1257366
Drug: Cannabis cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis cigarettes delivering 7 mg delta9-THC; administered during four training sessions and tested in the drug condition.
Study: 1257366
Drug: Non-drug condition;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug condition; subjects trained without cannabis.
Study: 31976814
Drug: Amlodipine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5-10 mg/day)
Study: 31976814
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (12.5-25 mg/day)
Study: 30659611
Drug: INP104 1.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: INP104 1.45 mg
Study: 30659611
Drug: IV DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV DHE 1.0 mg
Study: 30659611
Drug: Migranal 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migranal 2.0 mg
Study: 26095948
Drug: Rotigotine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (titrated over 1-7 weeks to optimal dose ≤8 mg/24 h for patients not receiving levodopa, ≤16 mg/24 h for patients receiving levodopa)
Study: 18060659
Drug: Decreased triacylglycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased triacylglycerol (per 1 mmol l(‐1) year(‐1)) in IFG individuals
Study: 10850898
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (30-minute massage with cocoa butter, twice a week for 5 weeks)
Study: 6149965
Drug: BW 825C
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW 825C (4 mg)
Study: 6149965
Drug: BW 825C
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW 825C (8 mg)
Study: 30738171
Drug: GBR 830
Normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBR 830 (10 mg/kg intravenous on day 1 and day 29)
Study: 24479760
Drug: Tai Chi-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi-based exercise program via telerehabilitation (45-minute session twice a week for eight consecutive weeks)
Study: 24479760
Drug: Tai Chi-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi-based exercise program provided in person at home (45-minute session twice a week for eight consecutive weeks)
Study: 8573430
Drug: Tiludronate therapy
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate therapy for 3 years
Study: 8573430
Drug: Tiludronate therapy
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate therapy for 2 years (non-fracture studies)
Study: 2092187
Drug: Nimesulide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (400 mg/die, 2 suppositories per day)
Study: 2092187
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 mg/die, 2 suppositories per day)
Study: 392743
Drug: Myc 2095
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myc 2095 (20 mg)
Study: 392743
Drug: triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone hexacetonide (20 mg)
Study: 31903712
Drug: Exenatide (EXE)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EXE) once weekly (2 mg/wk subcutaneously)
Study: 25179153
Drug: 500 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 µg nitroglycerin
Study: 19860883
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of triamcinolonacetonide (TCA)
Study: 14975474
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin E (800 IU per day) and C (1000 mg per day)
Study: 21255766
Drug: Mental health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental health treatment
Study: 11329998
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for anxiety and depression
Study: 9221995
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and aspirin
Study: 8073693
Drug: M‐1 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐1 daily in a dose of 15‐50 g, fish oil in a dose of 10‐30 ml
Study: 28858279
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with bracket-systems and dental foam (Splat, Russia) after meal (Group 3)
Study: 28858279
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with bracket-systems (Group 2)
Study: 28858279
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no orthodontic treatment (n=35)
Study: 20725117
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (25 g.day(‐1) for 5 days, followed by 5 g.day(‐1) for 3 days)
Study: 18670219
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg daily for 3 days)
Study: 7861015
Drug: Stavudine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (daily doses ranging from 0.1 to 12.0 mg/kg)
Study: 7861015
Drug: Stavudine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (doses of < or = 2 mg/kg/day, n = 216)
Study: 6894241
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg azidocillin tablets
Study: 6894241
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg azidocillin tablets
Study: 6894241
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg azidocillin tablets
Study: 6894241
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg azidocillin suspension
Study: 6894241
Drug: 799 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 799 mg azidocillin i.m. injection
Study: 6894241
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg azidocillin tablets twice daily for 14 days
Study: 6894241
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg azidocillin i.v. dosage
Study: 6894241
Drug: i.m. azidocillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. azidocillin dose
Study: 6894241
Drug: i.v. azidocillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. azidocillin doses
Study: 6894241
Drug: other dosage
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: other dosage forms of azidocillin
Study: 6894241
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration of azidocillin
Study: 28811737
Drug: Pedometer-assessed daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-assessed daily steps
Study: 28811737
Drug: Accelerometer-assessed minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerometer-assessed minutes of daily moderate-to-vigorous PA
Study: 28811737
Drug: Self-reported minutes
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported minutes of weekly walking and moderate- and vigorous-intensity PA
Study: 21211558
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon 2,000 mg/day
Study: 21211558
Drug: Metformin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,000 mg/day
Study: 21211558
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon 500 mg/day
Study: 21211558
Drug: Bitter melon
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter melon 1,000 mg/day
Study: 15285981
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in awareness associated with treatment
Study: 9397292
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30-120 mg/day
Study: 9397292
Drug: Enalapril 5-30
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5-30 mg/day
Study: 786807
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotic cover)
Study: 30010353
Drug: Tension Tamer
Normalized name: Ascorbic Acid/Chamomile/Cyanocobalamin/Kava/Magnesium/Pyridoxine/St John's Wort 150 MG-100 MG-0.006 MG-100 MG-25 MG-3 MG-50 MG Oral Capsule [TENSION TAMER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tension Tamer (TT) guided BAM sessions for 5-min intervals twice daily
Study: 30010353
Drug: Tension Tamer
Normalized name: Ascorbic Acid/Chamomile/Cyanocobalamin/Kava/Magnesium/Pyridoxine/St John's Wort 150 MG-100 MG-0.006 MG-100 MG-25 MG-3 MG-50 MG Oral Capsule [TENSION TAMER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tension Tamer (TT) guided BAM sessions for 10-min intervals twice daily
Study: 30010353
Drug: Tension Tamer
Normalized name: Ascorbic Acid/Chamomile/Cyanocobalamin/Kava/Magnesium/Pyridoxine/St John's Wort 150 MG-100 MG-0.006 MG-100 MG-25 MG-3 MG-50 MG Oral Capsule [TENSION TAMER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tension Tamer (TT) guided BAM sessions for 15-min intervals twice daily
Study: 28768474
Drug: Progesterone treatment
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone treatment (meta-analysis)
Study: 20624257
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (200 mg of iron sucrose) and recombinant human erythropoietin‐β (3000 IU)
Study: 14714012
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg, clarithromycin 250 mg and metronidazole 500 mg regimen, all drugs given twice daily for 7 days
Study: 10933004
Drug: Gel materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel materials
Study: 8780106
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment (prednisolone plus azathioprine)
Study: 1344473
Drug: Ranitidine (control)
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine (control) twice daily
Study: 1344473
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg once daily
Study: 6421560
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen of insulin and sulphonylurea (glibenclamide) for ten days, followed by ten days of insulin alone, followed by six months of combined treatment
Study: 6421560
Drug: Renewed combined
Normalized name: Renewal
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Renewed combined treatment with sulphonylurea and insulin
Study: 6421560
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with sulphonylurea and insulin
Study: 28683243
Drug: 15 grams
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 grams of protein distributed across 2 isoenergetic carbohydrate-containing beverages (15 and 240 min postexercise) with varying amounts of protein (0 + 15 g, 5 + 10 g, 10 + 5 g, and 15 + 0 g)
Study: 23932244
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (60-min sessions weekly for 8 weeks)
Study: 23932244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly regular day-care program)
Study: 15071842
Drug: Nootropil 70
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropil 70 mg/kg daily
Study: 15071842
Drug: Nootropil 40
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropil 40 mg/kg daily
Study: 11408983
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin sodium
Study: 27875061
Drug: Glycemic control
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycemic control target of 140 mg/dL
Study: 27875061
Drug: Glycemic control
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycemic control target of 180 mg/dL
Study: 25522919
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection (1 ml containing 40 mg methylprednisolone acetate and 10 mg lidocaine hydrochloride)
Study: 24022261
Drug: Once-weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly iron supplements (200 mg ferrous sulphate containing 63 mg of elemental iron) for 24 weeks
Study: 24022261
Drug: Twice-weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly iron supplements (200 mg ferrous sulphate containing 63 mg of elemental iron) for 12 weeks
Study: 24022261
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron supplements
Study: 9068511
Drug: Angiography after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiography after treatment with thrombolytics
Study: 7513437
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg/die
Study: 7513437
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg/die
Study: 7513437
Drug: Placebo (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (first year), then Finasteride 5 mg/die (second year)
Study: 25808116
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day of milled flaxseed
Study: 25808116
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of milled flaxseed
Study: 25808116
Drug: All flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All flaxseed doses
Study: 25808116
Drug: 40 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/day of milled flaxseed
Study: 16042224
Drug: IFNbeta‐1a (Avonex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a (Avonex) once weekly
Study: 16042224
Drug: IFNbeta three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta three times weekly (Rebif and Betaferon)
Study: 16042224
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with immunomodulatory drugs (IDs)
Study: 12183255
Drug: 1263W94 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1263W94 (100, 200, or 400 mg three times a day, or 600, 900, or 1,200 mg twice a day)
Study: 10624380
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg, three times daily for 24 weeks
Study: 10624380
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, three times daily for 24 weeks
Study: 2258339
Drug: Pefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (400 mg, iv, 8-hourly) for 5-30 days
Study: 2258339
Drug: Imipenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (1 g, iv, 8-hourly) for 5-30 days
Study: 31959342
Drug: Standard-dose radium-223
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose radium-223 (55 kBq/kg every 4 weeks for six cycles)
Study: 31959342
Drug: High-dose radium-223
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radium-223 (88 kBq/kg every 4 weeks for six cycles)
Study: 31959342
Drug: High-dose vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vs Standard-dose
Study: 31959342
Drug: Standard-dose radium-223
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose radium-223
Study: 31959342
Drug: High-dose radium-223
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radium-223
Study: 21349878
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with a scalpel
Study: 21349878
Drug: Percutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous treatment with a needle
Study: 17715118
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 900 mg injection 1 hour before and immediately after contrast medium injection, plus hydration
Study: 12612144
Drug: Campbell's Condensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campbell's Condensed Tomato Soup (CS) - 35 +/- 1 mg lycopene/d
Study: 12612144
Drug: Campbell's Ready
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campbell's Ready To Serve Tomato Soup (RTS) - 23 +/- 1 mg lycopene/d
Study: 12612144
Drug: V8 Vegetable
Normalized name: VEGETABLE CARBON
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: V8 Vegetable Juice (V8) - 25 +/- 1 mg lycopene/d
Study: 12612144
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups after treatment
Study: 10373348
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human insulin-like growth factor-I (rhIGF-I; 1.5 microg/kg/h)
Study: 10373348
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant human insulin-like growth factor-I (rhIGF-I; 9.0 microg/kg/h)
Study: 6770399
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (up to 10 mg)
Study: 22277556
Drug: Riboflavin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (1.6 mg/d for 16 wk)
Study: 19281446
Drug: Normal Level
Normalized name: GE100 Normal Level Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Level of Replacement Therapy
Study: 19281446
Drug: Augmented Level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Level of Replacement Therapy
Study: 17685917
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with routine infusions of factor VIII (FVIII) concentrate
Study: 17685917
Drug: On-demand FVIII
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand FVIII treatment
Study: 17685917
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose frequency of prophylaxis
Study: 9641318
Drug: External tones
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: External tones presented as 250 ms pulses, twice a second.
Study: 9641318
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of aspirin by one subject.
Study: 8086551
Drug: iv clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv clindamycin (900 mg every 8 hours for 10 days, then oral clindamycin (450 mg every 6 hours for 11 days) + oral primaquine (30 mg once daily)
Study: 8086551
Drug: oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral clindamycin (600 mg every 8 hours) + oral primaquine (30 mg once daily)
Study: 31857511
Drug: SVV-guided fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVV-guided fluid therapy (group S)